Health
Bezlotoxumab reduces odds of recurrent C. difficile infection in transplant recipients – Healio
Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant…
Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant and hematopoietic-cell transplant recipients, according to a study published in Open Forum Infectious Diseases.
“Solid-organ and…
Continue Reading
-
Business21 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Business23 hours ago5 easy steps to build a $100,000 ASX share portfolio
-
Noosa News23 hours agoThe rent crisis behind Australia’s two-faced cities
-
Noosa News20 hours agoThe Almond Ashes sees Australia and India mix business and cricket